Literature DB >> 22882326

FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.

Rute A Tomaz1, Inês Sousa, Joana G Silva, Catarina Santos, Manuel R Teixeira, Valeriano Leite, Branca M Cavaco.   

Abstract

OBJECTIVE: FOXE1 is a transcription factor required for thyroid differentiation and function. FOXE1 locus polymorphisms (chromosome 9q22.33) were recently associated with increased sporadic thyroid cancer risk. In this study, we aimed to investigate the association of FOXE1 variants with nonmedullary thyroid cancer (NMTC), in both sporadic and familial (FNMTC) cases from the Portuguese population. DESIGN AND METHODS: Nine variants located at the FOXE1 locus were sequenced in genomic DNA from 60 FNMTC probands and 80 patients with sporadic NMTC. Alleles were tested for association with thyroid cancer, against 130 healthy matched Portuguese controls.
RESULTS: All variants were significantly associated with increased thyroid cancer risk when combining familial and sporadic cases (OR range = 1·62-2·58). In particular, two reported risk variants were associated with the disease: rs965513 (allele A) with familial (OR = 2·30, 95% CI = 1·48-3·59, P = 0·0002) and sporadic (OR = 2·81, 95% CI = 1·87-4·22, P < 0·0001) NMTC and rs1867277 (allele A) with the sporadic (OR = 1·76, 95% CI = 1·18-2·62, P = 0·0052) and combined NMTC cases (OR = 1·70, 95% CI = 1·21-2·40, P = 0·0022). Interestingly, we also identified association of FOXE1 polyalanine tract expansions (>14 alanines) with thyroid cancer risk, in both familial (OR = 2·56, 95% CI = 1·64-4·01, P < 0·0001) and sporadic (OR = 2·44, 95% CI = 1·61-3·68, P < 0·0001) cases.
CONCLUSIONS: We found compelling evidence of association between FOXE1 variants and thyroid cancer risk in the Portuguese population. To our knowledge, this is the first study supporting the association of this locus with both sporadic and familial NMTC susceptibility.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882326     DOI: 10.1111/j.1365-2265.2012.04505.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  22 in total

1.  TITF1 and TITF2 loci variants indicate significant associations with thyroid cancer.

Authors:  Peiliang Geng; Juanjuan Ou; Jianjun Li; Yunmei Liao; Ning Wang; Ganfeng Xie; Rina Sa; Chen Liu; Lisha Xiang; Houjie Liang
Journal:  Endocrine       Date:  2015-07-25       Impact factor: 3.633

2.  Common genetic variants on FOXE1 contributes to thyroid cancer susceptibility: evidence based on 16 studies.

Authors:  Yixin Zhuang; Weixin Wu; Han Liu; Weixin Shen
Journal:  Tumour Biol       Date:  2014-04-18

3.  Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population.

Authors:  Alice J Sigurdson; Alina V Brenner; James A Roach; Lilia Goudeva; Jörg A Müller; Kai Nerlich; Christoph Reiners; Robert Schwab; Liliane Pfeiffer; Melanie Waldenberger; Melissa Braganza; Li Xu; Erich M Sturgis; Meredith Yeager; Stephen J Chanock; Ruth M Pfeiffer; Michael Abend; Matthias Port
Journal:  Carcinogenesis       Date:  2016-04-28       Impact factor: 4.944

4.  The investigation of foxe1 variations in papillary thyroid carcinoma.

Authors:  Erkan Somuncu; Adem Karatas; Sina Ferahman; Neslihan Saygili; Eren Yilmaz; Oguz Ozturk; Metin Kapan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).

Authors:  Joana S Pereira; Joana Gomes da Silva; Rute Alexandra Tomaz; António Evaristo Pinto; Maria João Bugalho; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

6.  A single nucleotide polymorphism associated with isolated cleft lip and palate, thyroid cancer and hypothyroidism alters the activity of an oral epithelium and thyroid enhancer near FOXE1.

Authors:  Andrew C Lidral; Huan Liu; Steven A Bullard; Greg Bonde; Junichiro Machida; Axel Visel; Lina M Moreno Uribe; Xiao Li; Brad Amendt; Robert A Cornell
Journal:  Hum Mol Genet       Date:  2015-02-04       Impact factor: 6.150

7.  FOXE1 association with differentiated thyroid cancer and its progression.

Authors:  Marissa Penna-Martinez; Friederike Epp; Heinrich Kahles; Elizabeth Ramos-Lopez; Nora Hinsch; Martin-Leo Hansmann; Ivan Selkinski; Frank Grünwald; Katharina Holzer; Wolf O Bechstein; Stefan Zeuzem; Christian Vorländer; Klaus Badenhoop
Journal:  Thyroid       Date:  2014-01-29       Impact factor: 6.568

8.  Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer.

Authors:  Huiling He; Wei Li; Sandya Liyanarachchi; Mukund Srinivas; Yanqiang Wang; Keiko Akagi; Yao Wang; Dayong Wu; Qianben Wang; Victor Jin; David E Symer; Rulong Shen; John Phay; Rebecca Nagy; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 9.  Molecular approaches to thyroid cancer diagnosis.

Authors:  Susan J Hsiao; Yuri E Nikiforov
Journal:  Endocr Relat Cancer       Date:  2014-05-14       Impact factor: 5.678

10.  Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.

Authors:  Huiling He; Wei Li; Sandya Liyanarachchi; Jaroslaw Jendrzejewski; Mukund Srinivas; Ramana V Davuluri; Rebecca Nagy; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.